USA: In a post hoc analysis of the ADJUST-T1D trial, adults with type 1 diabetes receiving once-weekly semaglutide 1 mg showed a significant reduction in total daily insulin dose by 4 weeks, ...

INCHEON, South Korea, Nov. 26, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that a post-hoc analysis of the LIBERTY-CD study, which showed that the efficacy of ZYMFENTRA® (infliximab-dyyb) is ...

62.7% relative reduction in mortality at day 30, which persisted through day 60, for patients treated with Auxora versus placebo in subset of patients in CARDEA with AKI The new data presented were ...

In the initial EXXELERATE trial comparing the efficacy of CIMZIA and adalimumab, the primary endpoints of superiority were not met. In the post hoc analysis, efficacy outcomes in CIMZIA and adalimumab ...

The same analysis performed on data from the similarly designed SELECT-PsA 1 trial in psoriatic arthritis showed similar ...

SAN DIEGO, Sept. 21, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) (Nasdaq: NBIX), today announced that it will present a new post hoc analysis of Phase 2 data of the investigational drug ...

In a post-hoc analysis of the DELIVER trial, interictal periods were longer with VYEPTI compared to placebo and corresponded to higher patient-reported quality of life outcomes Individuals taking ...

– Analysis further supports obesity-associated dysregulated aldosterone as an endotype predictive of enhanced response to lorundrostat treatment in patients with uncontrolled or treatment-resistant ...

Daratumumab-lenalidomide maintenance significantly increases MRD-negative conversion and reduces progression risk in multiple ...